While elevated miR-150 expression is associated with poorer clinical outcome in nonsmall-cell lung cancer [116] as well as triple negative breast cancer [117], miR-4734 has been recently identified in breast cancer by extensive next-generation sequencing analysis and encodes within the ERBB2/Her2 gene, which is upregulated in HER2-positive breast cancer patients [118]. This evidence concerns the gene ERBB2 and breast carcinoma.